1 |
[14c]-rpc1063 solution (0.1 mg/ml) for oral administration |
- |
- |
- |
- |
013 3件: 13, 96, 97 💬 |
2 |
Administration |
- |
- |
- |
- |
019 1件: 19 💬 |
3 |
Administration of a high dose of desipramine |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
156 1件: 156 💬 |
4 |
Administration of a low dose of desipramine |
Desipramine |
2件: D00812 D00812, D07791 D07791 💬 |
SLC6A2 2件: SLC6A2, SLC6A4 💬 |
Serotonergic synapse 2件: Serotonergic synapse, Synaptic vesicle cycle |
156 1件: 156 💬 |
5 |
Administration of an ace-inhibitor or not |
- |
- |
- |
- |
210 1件: 210 💬 |
6 |
Administration of cimzia® |
- |
- |
- |
- |
046 1件: 46 💬 |
7 |
Administration of drug (interferon-gamma 1-b) subcutaneously |
- |
- |
- |
- |
065 1件: 65 💬 |
8 |
Administration of rituximab and methylprednisolone |
Methylprednisolone |
7件: D00407 D00407, D00751 D00751, D00979 D00979, D02994 D02994, D05000 D05000, D05001 D05001, D05002 D05002 💬 |
MS4A1 2件: MS4A1, NR3C1 💬 |
Hematopoietic cell lineage 2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction |
051 1件: 51 💬 |
9 |
Administration of stable isotope-labelled leucine- |
Leucine |
1件: D00030 D00030 💬 |
- |
- |
006 1件: 6 💬 |
10 |
Avandia administration for 6-12 weeks |
- |
- |
- |
- |
265 1件: 265 💬 |
11 |
Behavioral: administration of probiotic (l. rhamnosus and l. acidophilus) |
Lactobacillus acidophilus |
1件: D04349 D04349 💬 |
- |
- |
097 1件: 97 💬 |
12 |
Biological : i10e (human normal immunoglobulin for intravenous administration 100mg/ml) |
Human immunoglobulin G |
- |
- |
- |
014 1件: 14 💬 |
13 |
Biological: kiovig® (human normal immunoglobulin for intravenous administration 100mg/ml) |
Human immunoglobulin G |
- |
- |
- |
014 1件: 14 💬 |
14 |
Bosentan administration |
Bosentan |
2件: D01227 D01227, D07538 D07538 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
086 1件: 86 💬 |
15 |
Device: administration kit |
- |
- |
- |
- |
019 1件: 19 💬 |
16 |
Device: nirs after bosentan administration |
Bosentan |
2件: D01227 D01227, D07538 D07538 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
17 |
Device: tcd after bosentan administration |
Bosentan |
2件: D01227 D01227, D07538 D07538 💬 |
EDNRA 2件: EDNRA, EDNRB 💬 |
Calcium signaling pathway 9件: Calcium signaling pathway, Melanogenesis, Neuroactive ligand-receptor interaction, Pathways in cancer, Relaxin signaling pathway, Renin secretion, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway |
013 1件: 13 💬 |
18 |
Docosahexaenoic acid administration: 50 mg/kg/day during 12 months |
Doconexent |
- |
- |
- |
299 1件: 299 💬 |
19 |
Growth hormone administration for 6 months |
Somatotropin |
1件: D02691 D02691 💬 |
GHR 1件: GHR 💬 |
Cytokine-cytokine receptor interaction 5件: Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway |
078 1件: 78 💬 |
20 |
Human normal 10% immunoglobulin for intravenous administration |
- |
- |
- |
- |
014 1件: 14 💬 |
21 |
Human normal 10% immunoglobulin for intravenous administrationn |
- |
- |
- |
- |
014 1件: 14 💬 |
22 |
Human normal immunoglobulin for intravenous (iv) administration |
Human immunoglobulin G |
- |
- |
- |
051 1件: 51 💬 |
23 |
Human normal immunoglobulin for intravenous administration |
Human immunoglobulin G |
- |
- |
- |
014 3件: 14, 51, 65 💬 |
24 |
Human normal immunoglobulin for subcutaneous administration |
Human immunoglobulin G |
- |
- |
- |
051 2件: 51, 65 💬 |
25 |
Human normal immunoglobulin for subcutaneous administration (igsc) |
Human immunoglobulin G |
- |
- |
- |
065 1件: 65 💬 |
26 |
Intrathecal administration of autologous msc-np |
- |
- |
- |
- |
013 1件: 13 💬 |
27 |
Intravenous administration of 1 million of msc |
- |
- |
- |
- |
002 1件: 2 💬 |
28 |
Intravenous administration of 2 million of msc |
- |
- |
- |
- |
002 1件: 2 💬 |
29 |
Intravenous administration of 4 million of msc |
- |
- |
- |
- |
002 1件: 2 💬 |
30 |
Intravenous administration of ferric carboxymaltose |
Ferric carboxymaltose |
1件: D08920 D08920 💬 |
- |
- |
086 1件: 86 💬 |
31 |
Levodopa (drug), intraduodenal administration |
Levodopa |
1件: D00059 D00059 💬 |
DRD1 5件: DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 11件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway |
006 1件: 6 💬 |
32 |
Levodopa and carbidopa solution for sc administration |
Carbidopa |
2件: D00059 D00059, D00558 D00558 💬 |
DDC 6件: DDC, DRD1, DRD2, DRD3, DRD4, DRD5 💬 |
Alcoholism 16件: Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Phenylalanine metabolism, Rap1 signaling pathway, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism, cAMP signaling pathway |
006 1件: 6 💬 |
33 |
Low-dose il-2 administration |
Human interleukin-2 |
- |
- |
- |
096 1件: 96 💬 |
34 |
Methotrexate + biologic administration |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 1件: 46 💬 |
35 |
Methotrexate + salazopyrine + hydroxychloroquine administration |
Hydroxychloroquine |
3件: D00142 D00142, D02115 D02115, D08050 D08050 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 1件: 46 💬 |
36 |
Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 1件: 46 💬 |
37 |
Methotrexate(mtx) administration is at the discretion of the rheumatologist and no tradename is fixed by the protocol. |
Methotrexate |
2件: D00142 D00142, D02115 D02115 💬 |
DHFR 2件: DHFR, DHFR2 💬 |
Antifolate resistance 5件: Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate |
046 1件: 46 💬 |
38 |
Other: questionnaire administration |
- |
- |
- |
- |
016 4件: 16, 34, 51, 298 💬 |
39 |
Other: tobramycin time of administration |
Tobramycin |
2件: D00063 D00063, D02542 D02542 💬 |
- |
- |
299 1件: 299 💬 |
40 |
Procedure: iv administration of genetically engineered hematopoietic stem/progenitors cells (hspcs) |
- |
- |
- |
- |
285 1件: 285 💬 |
41 |
Qr-313 gel for topical (cutaneous) administration |
- |
- |
- |
- |
036 1件: 36 💬 |
42 |
Raav1-cmv-gaa (study agent) administration |
- |
- |
- |
- |
256 1件: 256 💬 |
43 |
Semi continuous intra-oral administration of ld/cd |
- |
- |
- |
- |
006 1件: 6 💬 |
44 |
Subcutanious administration |
- |
- |
- |
- |
046 1件: 46 💬 |